Novo Nordisk and Eli Lilly's stocks took a hit after Hims & Hers announced a $49 version of the Wegovy pill, a significant discount from the original price of $149. This move has sparked debate among investors and healthcare professionals alike. The telehealth company claims its product is 'personalized' and legal, despite the patent protection of semaglutide, the active ingredient in Wegovy, until 2032. Hims & Hers argues that their compounded semaglutide uses a different formulation and delivery system, allowing for a once-a-day oral option that avoids needles and caters to those with specific needs. While Novo Nordisk's CEO reported 170,000 people already taking the medication, Eli Lilly is expected to launch a rival pill in the first half of the year, pending FDA approval. This development raises questions about the future of weight-loss drug pricing and the potential impact on both pharmaceutical companies and patients.
